Market News & Trends
Vetter's New Commercial Filling Line Ready for cGMP Filling
Vetter recently announced that its new award-winning filling line at the company's Ravensburg Vetter South facility is fully validated and ready for cGMP filling, after…
Biodel Completes Phase II Enrollment in Clinical Trial of Ultra-Rapid-Acting Insulin
Biodel Inc. recently announced the completion of patient enrollment in a Phase II clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of…
Foster Delivery Science Receives Grant to Develop Process for Oral Dose Drug Delivery
Foster Delivery Science recently announced it has been awarded a Manufacturer's Technical Assistance Program (MTAP) grant from the University of Connecticut for development of novel…
Medicyte Signs Development Agreement With Life Technologies
Medicyte recently announced it has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next-generation,…
RedHill Biopharma Submits NDA for Oral Thin Film Drug
RedHill Biopharma Ltd. recently announced the company and its co-development partner, IntelGenx Corp., have submitted a New Drug Application (NDA) to the USFDA seeking marketing…
VIVUS Announces $110-Million Synthetic Capped Royalty Financing
VIVUS, Inc. recently announced that it has entered into a $110-million non-equity financing with an investment fund managed by Pharmakon Advisors. Under the terms of…
Aastrom Biosciences Announces Strategic Change in R&D Programs
Aastrom Biosciences, Inc. recently announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T,…
Biogen's Injectable Drug Significantly Cuts Relapse Rate
Biogen Idec recently announced the positive, full first-year results from its 2-year pivotal Phase III ADVANCE study of PLEGRIDY (peginterferon beta-1a), the company's investigational candidate…
Cerecor Acquires Rights to COMT Inhibitors
Cerecor Inc. recently announced it has acquired exclusive, worldwide rights to develop, register, and commercialize agents that inhibit catechol-O-methyltransferase inhibitors (COMT inhibitors), previously discovered and…
Cook Pharmica Receives Additional Approval From US FDA
Cook Pharmica, which develops and manufactures pharmaceutical and biopharmaceutical products on a contract basis, recently received more good news from the US FDA. The company…
Enanta Pharmaceuticals Raises $56-Million in IPO
Enanta Pharmaceuticals, Inc. recently announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public…
OXiGENE Announces Patent Issuance for Novel Anticancer Class of Agents
OXiGENE, Inc. recently announced the US Patent and Trademark Office issued US Patent No. 8,397,859, covering certain benzosuberene-based compounds, including the analogues referred to as…
PerkinElmer Introduces Novel Non-Invasive Near-Infrared Imaging Agent
PerkinElmer recently introduced The GFR-Vivo 680 imaging agent, the first fluorescent agent that allows researchers to measure glomerular filtration rate (GFR) non-invasively, in vivo in…
Study Results for Two-Week Dosing Arm at Year 1
Primary Endpoint"¢ PLEGRIDY met the primary endpoint of reducing annualized relapse rate (ARR) at 1 year by 36% compared to placebo (p=0.0007). Secondary Endpoints"¢ PLEGRIDY…
OvaScience Announces Agreement for $35 Million Private Placement
OvaScience recently announced the execution of a securities purchase agreement with certain institutional and accredited investors providing for a private placement, or PIPE, financing. New…
Receptos Licenses AbbVie Antibody for Co-Development
Receptos Inc. recently announced it has entered a development license and option agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie. The asset,…
BioClinica & CoreLab Combination Creates Leader for Imaging Core Lab Services
BioClinica, Inc., recently announced that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and…
Boehringer Ingelheim Forms Joint Venture With Presidio Pharmaceuticals
Presidio Pharmaceuticals, Inc. recently announced a non-exclusive collaboration with Boehringer Ingelheim for a Phase IIa clinical trial of an interferon-free, all-oral, direct-acting antiviral (DAA) combination…
Ligand Signs Global License Deal With Spectrum
Ligand Pharmaceuticals Incorporated recently announced the signing of global license and supply agreements with Spectrum Pharmaceuticals, Inc. for the development and commercialization of Ligand's Captisol-enabled,…
Mesoblast Limited Completes $176 Million Private Placement
Regenerative medicine company Mesoblast Limited recently announced it has completed a private placement of its shares, raising A$170 million. Mesoblast now has cash reserves of…
